Kang Sang Kee, Woo Jung Hee, Kim Min Kook, Woo Sang Soo, Choi Jin Hyuk, Lee Hong Gu, Lee Nam Kyung, Choi Yun Jaie
School of Agricultural Biotechnology, Seoul National University, San 56-1, Sillimdong, Gwanakgu, Seoul 151-921, South Korea.
J Biotechnol. 2008 Jun 1;135(2):210-6. doi: 10.1016/j.jbiotec.2008.01.021. Epub 2008 Mar 10.
In this study, we demonstrated that the CSKSSDYQC-peptide ligand which was identified from a random phage-peptide library through an in vivo phage display technique with rats could prominently improve the transport efficiency of macromolecules, such as large filamentous phage particles (M13 bacteriophage), across the intestinal mucosal barrier. Synthetic CSKSSDYQC-peptide ligands significantly inhibited the binding of phage P1 encoding CSKSSDYQC-peptide ligands to the intestinal mucosal tissue and immunohistochemical analysis showed that the CSKSSDYQC-peptide ligands could be transported across the intestinal mucosal barrier via goblet cells as their specific gateway. Thus, we inferred that CSKSSDYQC-peptide ligand might have a specific receptor on the goblet cells and transported from intestinal lumen to systemic circulation by transcytosis mechanism. These results suggest that CSKSSDYQC-ligand could be a promising tool for development of an efficient oral delivery system for macromolecular therapeutics in the carrier-drug conjugate strategy.
在本研究中,我们证明了通过大鼠体内噬菌体展示技术从随机噬菌体肽库中鉴定出的CSKSSDYQC肽配体能够显著提高大分子物质(如大型丝状噬菌体颗粒(M13噬菌体))跨肠黏膜屏障的转运效率。合成的CSKSSDYQC肽配体显著抑制了编码CSKSSDYQC肽配体的噬菌体P1与肠黏膜组织的结合,免疫组织化学分析表明,CSKSSDYQC肽配体可通过杯状细胞作为其特定通道跨肠黏膜屏障转运。因此,我们推断CSKSSDYQC肽配体可能在杯状细胞上有特定受体,并通过转胞吞作用机制从肠腔转运至体循环。这些结果表明,在载体-药物偶联策略中,CSKSSDYQC配体可能是开发高效口服大分子治疗药物递送系统的一个有前景的工具。